A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy
Public ClinicalTrials.gov record NCT02238483. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients With a History of Frequent Acute Exacerbations While on Maintenance Therapy
Study identification
- NCT ID
- NCT02238483
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 213 participants
Conditions and interventions
Conditions
Interventions
- AZD7624 1.0 mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2014
- Primary completion
- Apr 3, 2016
- Completion
- Apr 3, 2016
- Last update posted
- May 23, 2018
2014 – 2016
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | 90036 | — |
| Research Site | Torrance | California | 90505 | — |
| Research Site | Denver | Colorado | 80206 | — |
| Research Site | Hialeah | Florida | 33013 | — |
| Research Site | Miami | Florida | 33176 | — |
| Research Site | Pembroke Pines | Florida | 33024 | — |
| Research Site | Atlanta | Georgia | 30310 | — |
| Research Site | Blue Ridge | Georgia | 30513 | — |
| Research Site | Baltimore | Maryland | 21224 | — |
| Research Site | St Louis | Missouri | 63141 | — |
| Research Site | Larchmont | New York | 10538 | — |
| Research Site | Charlotte | North Carolina | 28207 | — |
| Research Site | Wilmington | North Carolina | 28401 | — |
| Research Site | Akron | Ohio | 44302 | — |
| Research Site | Dayton | Ohio | 45459 | — |
| Research Site | Erie | Pennsylvania | 16508 | — |
| Research Site | Gaffney | South Carolina | 29340 | — |
| Research Site | Greenville | South Carolina | 29605 | — |
| Research Site | Rock Hill | South Carolina | 29732 | — |
| Research Site | Kingwood | Texas | 77339 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02238483, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 23, 2018 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02238483 live on ClinicalTrials.gov.